Advaxis' ADXS-503 Shows Durable Benefit Beyond One Year in Lung Cancer Patients Progressing on Merck's Keytruda

  • Advaxis Inc ADXS announced updated data from its Phase 1/2 study evaluating ADXS-503 in combination with Merck & Co Inc's Keytruda (pembrolizumab) in patients with metastatic non-small-cell lung cancer (NSCLC).
  • Data will be presented at the American Society of Clinical Oncology 2021 Annual Meeting.
  • The early results include a disease control rate of 44% from four out of 9 evaluable patients.
  • Clinical benefit was durable, with an observed partial response (PR) and stable disease (SD) sustained for over a year, and another observed SD lasting over six months.
  • An additional PR was maintained for approximately four months.
  • Translational data supports the potential of ADXS-503 to restore or enhance sensitivity to checkpoint inhibitors.
  • The combination therapy was well tolerated with no DLTS or added toxicity of the two drugs.
  • ADXS-503 is the first drug construct from the ADXS-HOT off-the-shelf, cancer-type specific immunotherapy program which targets hotspot mutations.
  • Price Action: ADXS shares are up 9.3% at $0.63 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareFDAMoversTrading IdeasGeneralBriefslung cancer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!